# Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

> **NCT03949842** · PHASE4 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists
- **DRUG:** Fluticasone furoate/umeclidinium/vilanterol

## Key facts

- **NCT ID:** NCT03949842
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06-27
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The decision to end the study was based on a change in GSK strategy. No subjects were enrolled into the study.
- **Last updated:** 2020-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03949842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03949842, "Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03949842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*